286. 遺伝性鉄芽球性貧血 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 7 / 薬物数 : 25 - (DrugBank : 10) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 64

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
ALA
   Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine
      2016   -   JPRN-UMIN000023490   Japan
Allogeneic bone marrow transplantation
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Aminolevulinic acid
   Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
      2016   -   JPRN-UMIN000021407   Japan
Biospecimen collection
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Bone marrow aspiration
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Bone marrow biopsy
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Computed tomography
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Deferasirox
   NOVARTIS FARMA
      2010   -   EUCTR2010-021062-29-IT   Greece;Italy;United Kingdom
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
Deferoxamine
   NOVARTIS FARMA
      2010   -   EUCTR2010-021062-29-IT   Greece;Italy;United Kingdom
   Novartis Pharma Services AG
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
Deferoxamine mesilate
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom
Desferal
   NOVARTIS FARMA
      2010   -   EUCTR2010-021062-29-IT   Greece;Italy;United Kingdom
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
DFO
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
Echocardiography
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Exjade
   NOVARTIS FARMA
      2010   -   EUCTR2010-021062-29-IT   Greece;Italy;United Kingdom
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
Fludarabine phosphate
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
ICL670
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
Lapine T-lymphocyte immune globulin
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Methotrexate
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Multigated acquisition scan
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Peripheral blood stem cell transplantation
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Phosphate
   Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine
      2016   -   JPRN-UMIN000023490   Japan
   Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
      2016   -   JPRN-UMIN000021407   Japan
Quality-OF-life assessment
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Tacrolimus
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Treosulfan
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
X-RAY imaging
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States